Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
Fred GebhartDuring the session, Dr. Hisao Asamura reviewed the criteria changes in the new 9th edition of the TNM classification recommendations. Read more
Novel, Targeted TKI Brings Hope to a Rare, Clinically Challenging Disease
Krithika Subramanian, PhDDr. Gerrina Ruiter says zongertinib shows encouraging preliminary findings in patients with HER2-mutated NSCLC. Read more
Study Results Support Continued Research of HER2-Targeted TKI
Fred GebhartDr. Xiuning Le presented data from a first-in-human trial that show a rapid, durable response in HER2-mutated NSCLC. Read more
Study Shows AI-Based Method Predicts Gene Mutation, Distribution in a More Timely, Accurate, and Economical Way Compared to NGS
Fred GebhartDr. Shan Xiong says the technology achieved robust and superior predictive performance across cancer genes of diverse types and across racial backgrounds. Read more
IASLC Recognizes Champions of Lung Cancer Advocacy and Research with STARS Scholar Program
Haleigh BehrmanThe IASLC’s Supportive Training for Advocates on Research and Science Program Provides Tools, Resources, and Education to Aspiring Patient Research Advocates. Read more
IASLC Looks Back at 50 Years of Growth, Collaboration, and Progress in Lung Cancer
Fred GebhartA special plenary at WCLC 2024 recognized a half-century of advances in thoracic oncology while reflecting on how far the IASLC has come since its first meeting. Read more
Study Shows Patients at Lowest Risk May Benefit from Longer Intervals Between Lung Cancer Screening
Fred GebhartDr. Annette McWilliams says the PanCan nodule management protocol demonstrates potential to streamline lung cancer screening and management processes. Read more
Analyzing the CheckMate Trials: How do Clinicians Choose the Winning Strategy for Patients With Resectable NSCLC?
Krithika Subramanian, PhDDuring WCLC 2024, Dr. Patrick Forde presented data from the CheckMate 77T and CheckMate 816 trials that may help guide lung cancer management in the near future. Read more
Phase II FLOWERS Trial Unveils Potential New First-Line Therapy Option
Fred GebhartResults from the study, presented by Dr. Jin-Ji Yang, suggest that a combination regimen of osimertinib plus savolitinib may be superior to osimertinib alone for EGFR-mutated NSCLC. Read more
Analysis of Membrane-Bound TROP2 in TROPION-Lung01 Underscores Seminal Advance in Lung Cancer Digital Pathology
Krithika Subramanian, PhDA novel computational pathology approach reveals the potential of TROP2 as a predictor of response to anti-TROP2 therapy in NSCLC. Read more